Global GLP 1 Market Poised for Explosive Growth, Surpassing USD 324 Billion by 2035

The global GLP-1 Market is expected to reach USD 324.5 billion by 2035, up from USD 54.5 billion in 2024. During the forecast period (2025 to 2035), the industry is projected to expand at a CAGR of 17.3%.

Over the next ten years, the industry is poised to grow 4.9X with an absolute dollar opportunity of USD 258.7 billion. This growth trajectory underscores a favorable outlook for the market, highlighting substantial potential for investment, innovation, and strategic partnerships across the pharmaceutical and biotechnology industries.

For More Insights into the Market, Request a Sample of this Report: https://www.factmr.com/connectus/sample?flag=S&rep_id=10786

Key Takeaways from Market Study:

The global GLP-1 market is projected to grow from USD 65.8 billion in 2025 to USD 324.5 billion by 2035, registering a strong CAGR of 17.3%.
This growth translates to an absolute dollar opportunity of USD 258.7 billion over the forecast period.
GLP-1 drugs are primarily used for managing type 2 diabetes and obesity, offering dual benefits of blood sugar regulation and weight loss.
Expanding research highlights potential in cardiovascular health and neurodegenerative diseases, while newer oral and once-weekly formulations are improving patient compliance.
North America remains the largest market, supported by high disease prevalence and robust healthcare infrastructure.
Changes in trade policy, such as recent tariffs on peptide precursors, are impacting manufacturing costs and supply chains.

Leading Players Driving Innovation in the GLP-1 Market:

Prominent players in the market are Novo Nordisk, Eli Lilly, AstraZeneca, Sanofi, Pfizer, Hanmi Pharmaceutical, and Biocon Ltd. among others.

Dual-Action Therapies Fuel Market Surge:

GLP‐1 therapies, known for their dual benefits of glucose regulation and appetite suppression, have emerged as a cornerstone in the management of type 2 diabetes and obesity. Their growing adoption stems from proven efficacy and the ability to address two major health conditions simultaneously.

Innovation Expands Reach:

The introduction of more patient-friendly formats-such as oral tablets and once-weekly injections-has improved compliance and boosted demand. Additionally, GLP‐1 drugs are increasingly being studied for new therapeutic areas, including cardiovascular and neurodegenerative diseases, expanding their clinical utility.

North America Maintains Market Leadership:

North America remains the dominant region in the GLP‐1 market, supported by a strong healthcare system, high prevalence of obesity and diabetes, and broad access to innovative treatmentsSupply-Chain Headwinds and Regulatory Nuances

Rising costs due to tariff-related impacts on peptide precursor imports and complex biologics manufacturing processes have added challenges to the supply chain. Cold-chain logistics and regulatory compliance remain key hurdles for manufacturers.

GLP-1 Market News:

In April 2025, Eli Lilly disclosed that its oral GLP-1 receptor agonist, orforglipron, produced statistically significant blood sugar and weight reductions in a Phase 3 trial. The once-daily oral pill reduced HbA1c by as much as 1.6% and body weight by 7.9%, with an expected safety profile in line with injectable GLP-1 treatments

Mangoceuticals introduced PeachesRx in February 2025, a women's telemedicine brand providing GLP-1 weight loss medications on a HIPAA-compliant platform. Focusing on the growing need for individualized well-being, PeachesRx blends convenience, accessibility, and medical supervision with the goal of dominating the women's health space with future expansion plans covering sexual wellness, hormone replacement, and beyond.

Browse Full Report: https://www.factmr.com/report/glp-1-market

More Valuable Insights on Offer:

Fact.MR, in its new offering, presents an unbiased analysis of the global GLP-1 Market, presenting historical data for 2020 to 2024 and forecast statistics for 2025 to 2035.

The GLP-1 market is segmented by drug type into Semaglutide, Liraglutide, Dulaglutide, Exenatide, and others. Administration routes include oral and injectable (subcutaneous). Key indications are type 2 diabetes, obesity, cardiovascular diseases, PCOS, and others. Distribution channels include hospital, retail, and online pharmacies. End-use segments are hospitals, specialty clinics, ambulatory surgical centers, and homecare.

Age groups covered are pediatric, adolescents, adults, geriatric, and women of reproductive age. Regions analyzed include North America, Latin America, Europe, Asia Pacific, and the Middle East & Africa.

Check out More Related Studies Published by Fact.MR Research:

Autopsy Tables Market - https://www.factmr.com/report/autopsy-tables-market

Sterile Injectable Drug Market - https://www.factmr.com/report/sterile-injectable-drug-market

Nizatidine Market - https://www.factmr.com/report/nizatidine-market

Vascular Closure Devices Market - https://www.factmr.com/report/vascular-closure-devices-market

Medical Equipment Cooling Market - https://www.factmr.com/report/medical-equipment-cooling-market

Contact Us:
US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
Sales Team : sales@factmr.com
Follow Us: LinkedIn | Twitter | Blog

About Us:
Fact.MR is a distinguished market research company renowned for its comprehensive market reports and invaluable business insights. As a prominent player in business intelligence, we deliver deep analysis, uncovering market trends, growth paths, and competitive landscapes. Renowned for its commitment to accuracy and reliability, we empower businesses with crucial data and strategic recommendations, facilitating informed decision-making and enhancing market positioning.

This release was published on openPR.